(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Smith presented an analysis of patient-reported health-related quality of life (HRQoL) based on the phase II open-label GALAHAD (NCT02854436) study of niraparib in mCRPC patients with DNA repair defects (DRD) who had progressed on prior taxane-based chemotherapy and androgen signaling inhibitor therapy.